ADRD - Invesco BLDRS Developed Markets 100 ADR Index Fund

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
21.31
+0.07 (+0.33%)
At close: 1:46PM EDT
Stock chart is not supported by your current browser
Previous Close21.24
Open21.14
Bid21.17 x 900
Ask21.28 x 800
Day's Range21.14 - 21.31
52 Week Range18.87 - 23.42
Volume1,041
Avg. Volume3,719
Net Assets36.15M
NAV21.19
PE Ratio (TTM)197.31
Yield3.73%
YTD Return9.62%
Beta (3Y Monthly)0.91
Expense Ratio (net)0.30%
Inception Date2002-11-13
Trade prices are not sourced from all markets
  • Sanofi’s Q3 Earnings: Analysts’ Estimates
    Market Realist7 months ago

    Sanofi’s Q3 Earnings: Analysts’ Estimates

    Sanofi (SNY) is one of the largest pharmaceutical companies. Since the company’s headquarters are in Paris, its reports its financial results in euros. Sanofi is set to release its third-quarter earnings on October 31. Wall Street analysts expect the EPS to be 1.71 euros on revenues of 9.32 billion euros during the third quarter.

  • How Novartis’s Alcon Performed in Third Quarter
    Market Realist7 months ago

    How Novartis’s Alcon Performed in Third Quarter

    Alcon, the eye care business of Novartis AG (NVS), includes surgical products and vision care products. Alcon reported revenues of ~$1.76 billion during the third quarter of 2018, a 3% increase in year-over-year (or YoY) revenues as compared to ~$1.71 billion in the third quarter of 2017. The growth was driven by a 5% growth in operating revenues, offset by a 2% negative impact of foreign exchange.

  • How Novartis’s Business Segments Performed in the Third Quarter
    Market Realist7 months ago

    How Novartis’s Business Segments Performed in the Third Quarter

    As discussed earlier, Novartis (NVS) missed Wall Street analysts’ estimates for revenues with reported revenues of ~$12.78 billion during the third quarter of 2018, a 2.9% increase in YoY revenues. Novartis AG is the holding company providing healthcare solutions, and its business is classified into three business segments including the Innovative Medicines segment, Sandoz, and Alcon. The below chart shows the revenue performance of Novartis’s segments since the first quarter of 2017. 

  • Analysts’ Estimates and Ratings for Novartis in October
    Market Realist7 months ago

    Analysts’ Estimates and Ratings for Novartis in October

    Novartis’s (NVS) revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.

  • How Novartis’s Businesses Have Been Performing
    Market Realist7 months ago

    How Novartis’s Businesses Have Been Performing

    Novartis’s (NVS) business is separated into three segments: Innovative Medicines, the prescription medicines business Sandoz, the generics business Alcon, the eye care business

  • GW Pharmaceuticals: Recommendations and Market Capitalization
    Market Realist8 months ago

    GW Pharmaceuticals: Recommendations and Market Capitalization

    GW Pharmaceuticals (GWPH) has developed prescription medicines derived from the cannabis plant for the treatment of spasticity from multiple sclerosis. Its portfolio includes clinical stage cannabinoid products focused on the treatment of neurological conditions.

  • GlaxoSmithKline ADR’s Performance and Revenues in Q3 2018
    Market Realist8 months ago

    GlaxoSmithKline ADR’s Performance and Revenues in Q3 2018

    GlaxoSmithKline (GSK) segregates its business portfolio into three business segments—Pharmaceuticals, Vaccines, and Consumer Healthcare. As a British multinational company, GlaxoSmithKline reports its revenues in pounds sterling. The chart below compares GlaxoSmithKline’s EPS and revenues since the first quarter of 2017, as well as its estimates for the third quarter.

  • How GlaxoSmithKline’s Vaccines Business Has Performed Recently
    Market Realist8 months ago

    How GlaxoSmithKline’s Vaccines Business Has Performed Recently

    GlaxoSmithKline’s (GSK) Vaccines segment includes influenza vaccines, meningitis vaccines, shingles vaccines, and established vaccines. The vaccines segment reported revenues of ~1.3 billion pounds during the second quarter of 2018, a 13% increase in YoY revenues. The growth includes a 16% increase in operating revenues offset by a 3% negative impact of foreign exchange during the quarter.

  • Novartis’s Key Developments in August
    Market Realist9 months ago

    Novartis’s Key Developments in August

    As we’ve already seen, Novartis (NVS) reported a 7% growth YoY (year-over-year) in revenues to ~$13.16 billion during Q2 2018.

  • Novartis’s Innovative Medicines Business in Q2 2018
    Market Realist9 months ago

    Novartis’s Innovative Medicines Business in Q2 2018

    As we’ve already seen, Novartis’s (NVS) Innovative Medicines business includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology. Innovative Medicines contributed ~67.4% of Novartis’s total revenues in Q2 2018, a 10% growth YoY (year-over-year) to $8.9 billion.

  • Analysts’ Recommendations for GlaxoSmithKline Stock
    Market Realist9 months ago

    Analysts’ Recommendations for GlaxoSmithKline Stock

    This year, analysts expect GlaxoSmithKline’s (GSK) revenue to grow 0.4% YoY (year-over-year) to ~30.3 billion British pounds from ~30.2 billion pounds, and its income margin to narrow YoY to 17.9% from 18.1%. They expect it to report EPS of 110.75 pence.

  • Analyzing GlaxoSmithKline’s Revenue Trends
    Market Realist9 months ago

    Analyzing GlaxoSmithKline’s Revenue Trends

    In the second quarter, GlaxoSmithKline’s (GSK) revenue was nearly flat YoY (year-over-year) at 7.3 billion British pounds, reflecting 4% growth at constant exchange rates offset by a 4% impact by foreign exchange. The pound strengthened, weakening GSK’s revenue. The chart below shows GlaxoSmithKline’s revenue since the first quarter of 2017.

  • Novartis’s Innovative Medicines Segment in Q2 2018
    Market Realist10 months ago

    Novartis’s Innovative Medicines Segment in Q2 2018

    Novartis’s (NVS) Innovative Medicines segment includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology. The segment contributed 67.4% of Novartis’s total revenues in the second quarter and reported a 10% growth YoY (year-over-year) at $8.9 billion.

  • A Look at GlaxoSmithKline’s Valuation on May 29
    Market Realistlast year

    A Look at GlaxoSmithKline’s Valuation on May 29

    GlaxoSmithKline (GSK) is focused on maintaining a sustainable growth model by strategizing its business beyond pharmaceuticals.